HUTCHMED (CHINA) LIMITED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has more than 4,600 personnel across all its companies, at the center of which is a team of over 1,500 in oncology/immunology. Since inception it has advanced 12 cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and marketed. For more information, please visit: www.hutch med.com or follow us on LinkedIn.
HUTCHMED (CHINA) LIMITED
Industry:
Biopharma Biotechnology Health Care Medical Pharmaceutical
Founded:
2000-01-01
Address:
Kowloon City, Kowloon, Hong Kong
Country:
Hong Kong
Website Url:
http://www.hutch-med.com
Total Employee:
1001+
Status:
Active
Contact:
+85221218200
Email Addresses:
[email protected]
Total Funding:
220.2 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS COVID-19 Proofpoint CSC Global DNS
Similar Organizations
Acasti Pharma
Acasti Pharma is an emerging biopharmaceutical company.
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Ascentage Pharma
Ascentage is a clinical-stage biopharmaceutical company that develops drugs for the treatment of cancer.
Frontier Biotechnologies
Frontier Biotechnologies is a commercial-stage bio-pharmaceutical company.
YS Biopharma
YS Biopharma is a global, fully integrated bio-pharmaceutical company.
Current Employees Featured
Founder
Stock Details
Investors List
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board investment in Post-IPO Equity - HUTCHMED (China) Limited
General Atlantic
General Atlantic investment in Post-IPO Equity - HUTCHMED (China) Limited
SBCVC
SBCVC investment in Venture Round - HUTCHMED (China) Limited
Mitsui & Co
Mitsui & Co investment in Venture Round - HUTCHMED (China) Limited
Key Employee Changes
| Date | New article |
|---|---|
| 2022-03-03 | HUTCHMED announces retirement of CEO and appointment of new CEO |
Official Site Inspections
http://www.hutch-med.com Semrush global rank: 2.57 M Semrush visits lastest month: 6.83 K
Unable to get host informations!!!
More informations about "HUTCHMED (China) Limited"
About Us - HUTCHMED
HUTCHMED is an innovative, commercial-stage biopharmaceutical company committed to the discovery and global development of targeted therapies and immunotherapies for the …See details»
What We Do - HUTCHMED
We have established our in-house commercial organization specializing in oncology and covering over 2,100 oncology hospitals and 20,000 oncology physicians in 30 provinces and cities in …See details»
HUTCHMED (China) Limited - Crunchbase Company …
Also Known As Chi-med, Hutchison MediPharma, HCM, 和黃醫藥, 和黃中國醫藥科技, Hutchison China Meditech (Chi-Med) Legal Name HUTCHMED (China) Limited; Stock Symbol SEHK:13 ; Company Type For Profit; Contact Email …See details»
HUTCHMED - LinkedIn
HUTCHMED | 11,337 followers on LinkedIn. Building a global science-focused biopharma from an established base in China. | HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, …See details»
Hutchmed | European Clinical Trials Information Network
Over the years, Hutchmed has grown through a series of mergers and acquisitions, including the acquisition of Chi-Med, a UK-based biotech company, in 2006. The company has also …See details»
HUTCHMED (China) Limited - Contacts, Employees, Board
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company.See details»
HUTCHMED (China) Ltd. (和黄医药（中国）有限公司)
Herein we describe the medicinal chemistry efforts that led to the discovery of the clinical-staged Syk inhibitor sovleplenib (41) via a structure-activity relationship investigation and pharmacokinetics (PK) optimization of a pyrido[3,4 …See details»
HUTCHMED - LinkedIn
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted ...See details»
HUTCHMED - Trinity Delta
Sep 25, 2024 HUTCHMED is steadily executing on its strategy to accelerate its path to sustainable profitability from FY25. This remains centred around commercial delivery and near …See details»
Change of Company Name - hutch-med.com
May 4, 2021 A dedicated organization of over 1,200 personnel has advanced ten cancer drug candidates from in-house discovery into clinical studies around the world, with its first two …See details»
HUTCHMED Announces Launch by Takeda of FRUZAQLA® …
Nov 22, 2024 According to the International Agency for Research on Cancer/World Health Organization, CRC is the third most prevalent cancer worldwide, associated with more than …See details»
HUTCHMED Announces Closing of Divestment of Non-Core OTC …
Sep 29, 2021 A dedicated organization of over 1,400 personnel has advanced eleven cancer drug candidates from in-house discovery into clinical studies around the world, with its first …See details»
Hutchmed - eqtgroup.com
Nov 29, 2024 HUTCHMED is an innovative, commercial-stage biopharmaceutical company committed to the discovery and global development of targeted therapies and …See details»
HUTCHMED to Receive First Commercial Milestone Payment …
Oct 31, 2024 According to the International Agency for Research on Cancer/World Health Organization, CRC is the third most prevalent cancer worldwide, associated with more than …See details»
News & Presentations - HUTCHMED
Aug 17, 2021 A dedicated organization of over 1,400 personnel has advanced eleven cancer drug candidates from in-house discovery into clinical studies around the world, with its first …See details»
How HUTCHMED Brought Regulatory Submissions In-House | Veeva
When Maria Ferrara joined HUTCHMED in 2020 as the senior director, head of regulatory operations and submissions for the U.S. and EU, she had a clear and pressing mandate: bring …See details»
News & Presentations - HUTCHMED
Mar 3, 2022 Continuing expansion of in-house oncology commercial organization in China, which at the end of 2021 numbered about 630 ... For more information, please visit: …See details»
News & Presentations - HUTCHMED
Established our U.S. commercial organization with the recruitment of senior leadership team based in New Jersey to prepare launch readiness for the potential ... For more information, …See details»
HUTCHMED Reports 2022 Full Year Results and Provides Business
Organization. Rapid initial self-pay uptake due to being the first -in-class selective MET inhibitor in China, expect continued uptake to be supported by NRDL inclusion starting March 1, 2023; • …See details»